Heterogeneous profile of LV remodeling in end-stage hypertrophic cardiomyopathy
This article has no abstract so we have provided the first paragraph of the full text.
A large, multicenter study of patients with hypertrophic cardiomyopathy (HCM) has indicated that the end stage of the disease is less frequent and more heterogeneous in clinical profile than was previously thought. Harris et al. analyzed 1,259 patients with HCM enrolled at three centers in the US and Italy. End-stage HCM was found in 44 (3.5%) patients; mean age at diagnosis was 45 years (range 14–74 years). The mortality for end-stage HCM was 11% per year, compared with 1% per year for the overall HCM population.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Opn: key regulator of pDC interferon productionNature Immunology News and Views (01 May 2006)
Etiologies of cardiomyopathy and heart failureNature Medicine News and Views (01 Mar 1999)
